Abstract: An integrated circuit (IC) die includes first through third adjacent rows of through-silicon vias (TSVs), and first and second adjacent rows of memory macros. TSVs of the first row of TSVs extend through and are electrically isolated from memory macros of the first row of memory macros. TSVs of the third row of TSVs extend through and are electrically isolated from memory macros of the second row of memory macros.

Abstract: In some embodiments, the present disclosure relates to an integrated chip that includes a first conductive structure arranged over a substrate. A memory layer is arranged over the first conductive structure, below a second conductive structure, and includes a ferroelectric material. An annealed seed layer is arranged between the first and second conductive structures and directly on a first side of the memory layer. An amount of the crystal structure that includes an orthorhombic phase is greater than about 35 percent.

Abstract: Polymer film and laminated glass manufactured using the polymer film are provided. The polymer film has a first surface and a second surface, wherein the first surface has a peak material volume (Vmp) at a material ratio of 10% ranging from 0.15 ?m3/?m2 to 1.20 ?m3/?m2 and a kurtosis (Sku) ranging from 0.73 to 10.02, wherein the material ratio, peak material volume, and kurtosis are defined in accordance with ISO 25178-2:2012.

Abstract: Methods and compositions for preparing and priming a tissue graft for an accelerated therapeutic effect are provided herein. In one embodiment, the method includes obtaining a tissue containing viable cells from a donor, wherein the viable cells are endogenous to the tissue and remain resident in the tissue; and priming the viable cells with one or more stimuli comprising simulated hypoxia to produce a primed tissue, wherein when grafted to a recipient the primed tissue provides a benefit compared to non-primed tissue.

Abstract: Methods are provided for treatment of several conditions of one or more body features, where the method comprises implanting an acellular soft tissue-derived matrix in, on, proximate to, or a combination thereof, the body feature, wherein the acellular soft tissue-derived matrix comprises a delipidated, decellularized adipose matrix. The delipidated, decellularized adipose tissue matrix is produced by delipidating an adipose tissue sample, followed by decellularizing the delipidated adipose tissue sample. The resulting matrix contains a proportion of lipids which is less than the proportion of lipids contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating. The delipidated, decellularized adipose matrix may be provided as particles, a slurry, a paste, a gel, an injectable form, or in some other form.

Abstract: A polymer film and a laminated glass manufactured using the polymer film are provided. The polymer film has a first surface and a second surface, wherein the first surface has a standard deviation of a void volume (Vv) value at a material ratio of 10% ranging from 0.5 ?m3/?m2 to 2.5 ?m3/?m2, and wherein the material ratio and void volume are defined in accordance with ISO 25178-2:2012.

Abstract: Methods are provided for treatment of several conditions of one or more body features, where the method comprises implanting an acellular soft tissue-derived matrix in, on, proximate to, or a combination thereof, the body feature, wherein the acellular soft tissue-derived matrix comprises a delipidated, decellularized adipose matrix. The delipidated, decellularized adipose tissue matrix is produced by delipidating an adipose tissue sample, followed by decellularizing the delipidated adipose tissue sample. The resulting matrix contains a proportion of lipids which is less than the proportion of lipids contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating. The delipidated, decellularized adipose matrix may be provided as particles, a slurry, a paste, a gel, an injectable form, or in some other form.

Abstract: A polymer film and laminated glass manufactured using the same are provided. The polymer film has a first surface and a second surface, wherein the first surface has a root mean square gradient (Sdq) ranging from 1.5 to 3 and a root mean square height (Sq) ranging from 8 ?m to 20 ?m, wherein the Sdq and Sq are defined in accordance with ISO 25178-2:2012.

Abstract: A polymer film and laminated glass manufactured using the same are provided. The polymer film has a first surface and a second surface, wherein the first surface has a root mean square gradient (Sdq) ranging from 0.1 to 1.5 and a root mean square height (Sq) ranging from 1 ?m to 15 ?m, wherein Sdq and Sq are defined in accordance with ISO 25178-2:2012.

Abstract: The present disclosure relates to a polymer film comprising at least one first layer and at least one second layer, the first layer and the second layer each comprising a polyvinyl acetal resin and a plasticizer; wherein the polymer film has a first loss factor peak value at ?20° C. to 20° C., and a second loss factor peak value at 20° C. to 50° C.; wherein the polymer film has a loss factor valley value between the first loss factor peak value and the second loss factor peak value, the loss factor valley value is 0.15 to 0.45, and the loss factor of the polymer film at 10° C. is less than 0.5. The polymer film can still maintain good sound insulation performance at a specific ambient temperature and/or after a period of time.

Abstract: A polymer film and laminated glass manufactured using the polymer film. The polymer film includes a first and second layer, and a third layer disposed between the first and second layers, and the two surfaces of the third layer are in contact with the first and second layers, respectively. The surface of the first layer that is not in contact with the third layer is a first surface, and the surface of the second layer not in contact with the third layer is a second surface, wherein the first surface has a void volume (Vv) value at a material ratio of 10% ranging from 3 ?m3/?m2 to 30 ?m3/?m2 and a dale void volume (Vvv) at a material ratio of 80% less than 2 ?m3/?m2, and the ratio of the maximum pit height (Sv) of the first surface to the thickness of the first layer is 0.2 or less.

Abstract: A polymer film and a laminated glass manufactured using the polymer film are provided. The polymer film has a first surface and a second surface, wherein the first surface has a standard deviation of a void volume (Vv) value at a material ratio of 10% ranging from 0.5 ?m3/?m2 to 2.5 ?m3/?m2, and wherein the material ratio and void volume are defined in accordance with ISO 25178-2:2012.

Abstract: Compositions including a first soft tissue-derived matrix and a second soft tissue-derived matrix are provided, as well as methods of making such compositions. In some embodiments, the composition comprises delipidated, decellularized adipose tissue-derived matrix and delipidated, decellularized fascial tissue-derived matrix, which may be combined in various proportions. Such adipose-fascia matrix compositions provide improved volume retention when implanted into a patient. The composition may further include exogenous cells or other substances, and/or a carrier. The composition is suitable for use in plastic surgery procedures, including reconstructive or cosmetic surgery procedures, as well as procedures for wound treatment and tissue regeneration.

Abstract: Preserved tissue samples contain endogenous viable cells and retain or promote biological activity after being stored at temperatures above freezing for extended periods of time (e.g., from 14 days to 3 years). The preserved tissue samples are implanted in or on a subject and, after rehydration, they retain beneficial biological activity, promote beneficial biological activity, or both. The beneficial biological activity comprises promoting one or more of tissue healing, tissue growth, and tissue generation. Methods for preparing the preserved tissue samples include contacting a recovered tissue sample with one or more protectants, followed by lyopreservation. Suitable protectants include sugars, polyphenols, carotenoids, and combinations thereof. Preferred protectants include glucose, fructose, sucrose, trehalose, dextran, EGCG, and combinations thereof. The recovered tissue sample may be any of several possible issue types.

Abstract: Compositions including a first soft tissue-derived matrix and a second soft tissue-derived matrix are provided, as well as methods of making such compositions. In some embodiments, the composition comprises dilapidated, decellularized adipose tissue-derived matrix and dilapidated, decellularized fascial tissue-derived matrix, which may be combined in various proportions. Such adipose-fascia matrix compositions provide improved volume retention when implanted into a patient. The composition may further include exogenous cells or other substances, and/or a carrier. The composition is suitable for use in plastic surgery procedures, including reconstructive or cosmetic surgery procedures, as well as procedures for wound treatment and tissue regeneration.

Abstract: Methods are provided for treatment of several conditions of one or more body features, where the method comprises implanting an acellular soft tissue-derived matrix in, on, proximate to, or a combination thereof, the body feature, wherein the acellular soft tissue-derived matrix comprises a delipidated, decellularized adipose matrix. The delipidated, decellularized adipose tissue matrix is produced by delipidating an adipose tissue sample, followed by decellularizing the delipidated adipose tissue sample. The resulting matrix contains a proportion of lipids which is less than the proportion of lipids contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating. The delipidated, decellularized adipose matrix may be provided as particles, a slurry, a paste, a gel, an injectable form, or in some other form.

Abstract: Decellularized muscle matrices are provided for use as implants and grafts to repair, regenerate, supplement, reinforce and replace muscle tissue. The decellularized muscle matrices are derived from muscle tissue having preserved extracellular matrix components, retained muscle-forming potential, and from which immunogenic components have been removed. The decellularized muscle matrices are produced in various physical forms and combinations. Methods for making and using the decellularized muscle matrices are also provided.

Abstract: An acellular soft tissue-derived matrix suitable for use as a medical graft or implant may comprise, for example, a delipidated, decellularized adipose tissue matrix. The delipidated, decellularized adipose tissue matrix is substantially free of substances that pose a significant risk of causing an immunogenic response in a patient receiving the matrix. Methods for producing the delipidated, decellularized adipose tissue matrix include the steps of delipidating an adipose tissue sample, followed by decellularizing the delipidated adipose tissue sample. The resulting delipidated, decellularized adipose tissue matrix contains a proportion of Type IV collagen which is greater than the proportion of Type IV collagen contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating.

Abstract: Methods and compositions for preparing and priming a tissue graft for an accelerated therapeutic effect are provided herein. In one embodiment, the method includes obtaining a tissue containing viable cells from a donor, wherein the viable cells are endogenous to the tissue and remain resident in the tissue; and priming the viable cells with one or more stimuli comprising simulated hypoxia to produce a primed tissue, wherein when grafted to a recipient the primed tissue provides a benefit compared to non-primed tissue.

Abstract: Compositions including a first soft tissue-derived matrix and a second soft tissue-derived matrix are provided, as well as methods of making such compositions. In some embodiments, the composition comprises dilapidated, decellularized adipose tissue-derived matrix and dilapidated, decellularized fascial tissue-derived matrix, which may be combined in various proportions. Such adipose-fascia matrix compositions provide improved volume retention when implanted into a patient. The composition may further include exogenous cells or other substances, and/or a carrier. The composition is suitable for use inplastic surgery procedures, including reconstructive or cosmetic surgery procedures, as well as procedures for wound treatment and tissue regeneration.